A share price of Abbott Laboratories [ABT] is currently trading at $120.92, up 1.32%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The ABT shares have gain 1.92% over the last week, with a monthly amount glided 6.07%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 6, March 2024, Real-World Data Show Abbott’s FreeStyle Libre® Systems and GLP-1 Medicines Work Better Together for People with Type 2 Diabetes. In a post published today on Yahoo Finance, Data analyses show that people with Type 2 diabetes using GLP-1 medicines saw a significant improvement in their HbA1C after adding FreeStyle Libre technology to their regimen.
From an analyst’s perspective:
Abbott Laboratories [NYSE: ABT] stock has seen the most recent analyst activity on July 21, 2023, when Wolfe Research upgraded its rating to a Peer Perform. Previously, Morgan Stanley downgraded its rating to Equal-Weight on May 30, 2023, and kept the price target unchanged to $112. On April 20, 2023, Wolfe Research reiterated its Underperform rating and revised its price target to $103 on the stock. UBS reiterated its Buy rating and increased its price target to $130 on April 20, 2023. Raymond James reiterated its recommendation of a Outperform and raised its price target to $123 on April 20, 2023. JP Morgan reiterated a Overweight rating for this stock on April 20, 2023, and upped its price target to $122. In a note dated April 20, 2023, Bernstein reiterated an Outperform rating on this stock and boosted its target price from $132 to $133.
Abbott Laboratories experienced fluctuations in its stock price throughout the past year between $89.67 and $120.60. Currently, Wall Street analysts expect the stock to reach $130.42 within the next 12 months. Abbott Laboratories [NYSE: ABT] shares were valued at $120.92 at the most recent close of the market. An investor can expect a potential return of 7.86% based on the average ABT price forecast.
Analyzing the ABT fundamentals
Trailing Twelve Months sales for Abbott Laboratories [NYSE:ABT] were 40.11B which represents 1.49% growth. Gross Profit Margin for this corporation currently stands at 0.54% with Operating Profit Margin at 0.17%, Pretax Profit Margin comes in at 0.17%, and Net Profit Margin reading is 0.14%. To continue investigating profitability, this company’s Return on Assets is posted at 0.08, Equity is 0.12 and Total Capital is 0.12. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.39.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 120.08 points at the first support level, and at 119.24 for the second support level. However, for the 1st resistance point, the stock is sitting at 121.63, and for the 2nd resistance point, it is at 122.34.
Abbott Laboratories [ABT] reported earnings per share of $1.19 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of $1.19/share, meaning a difference of $0 and a surprise factor of 0.00%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were $1.14 per share as compared to estimates of $1.1 per share, a difference of $0.04 representing a surprise of 3.60%.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Abbott Laboratories [NYSE:ABT] is 1.64. In addition, the Quick Ratio stands at 1.16 and the Cash Ratio stands at 0.5. Considering the valuation of this stock, the price to sales ratio is 5.23, the price to book ratio is 5.43 and price to earnings (TTM) ratio is 37.03.
Transactions by insiders
Recent insider trading involved Salvadori Daniel Gesua Sive, EXECUTIVE VICE PRESIDENT, that happened on Mar 01 ’24 when 963.0 shares were sold. EXECUTIVE VICE PRESIDENT, ALLEN HUBERT L completed a deal on Mar 01 ’24 to sell 853.0 shares. Meanwhile, EXECUTIVE VICE PRESIDENT Morrone Louis H. sold 801.0 shares on Mar 01 ’24.
